



# New Cancer Medicines: NHS and Industry Working Together


27<sup>th</sup> November 2009

**Meeting Chair: Steve Williamson**  
Consultant Pharmacist for Cancer Services,  
North of England Cancer Network



## Welcome & Introduction

**Steve Williamson**  
Consultant Pharmacist for Cancer Services,  
Northumbria NHFT &  
North of England Cancer Network



New Cancer Medicines: NHS and  
Industry Working Together

## Housekeeping


- Refreshments and lunch will be served in the Gateshead Foyer from 12.45 to 1.45pm
- Please switch off your mobile phones
- There is no fire-alarm test planned
  - If the fire alarm sounds please follow the fire exits and assemble outside the building
- Please complete your feedback form

New Cancer Medicines: NHS and  
Industry Working Together

## Overview of Today

- **NHS goals... my organisation goals.... my goal!**  
*'North East Cancer patients have fair access to the medicines they need for their cancer and I ensure they are used safely and effectively'*
- **What do I see as industry's goals....**  
*develop innovative new treatments which patients can get access to! run a successful business.... sell product and have happy customers and share holders*

## Why a develop a more Joint approach?



In current financial climate NHS cannot implement new high cost cancer medicines without co-operation of industry and industry cannot be successful without working with us

## Agenda

10.10–10.40	<b>NHS perspective: NECDAG and access to high-cost drugs</b> <i>Ken Bremner, CEO of Sunderland Hospitals and Chair of NECDAG</i>
10.40–11.10	<b>NHS perspective: Individual funding requests</b> <i>Mike Guy, Medical Director, NHS North of Tyne, Newcastle-upon-Tyne</i>
11.10–11.40	<b>Industry perspective: UK oncology market</b> <i>Amanda Cunnington, Head of Healthcare Development, Roche Products Ltd</i>
11.40–12.30	<b>Drug pricing in the UK: Risk share schemes here to stay</b>
11.40–12.05	<b>NHS perspective</b> <i>Allan Karr, Pharmacy Business Services Manager, University College London Hospital</i>
12.05–12.30	<b>Industry perspective</b> <i>Erik Bokmans, Director of Sales and Marketing, Celgene Ltd</i>
12.30–12.45	<b>Questions and answers</b>
12.45–13.45	<b>Lunch and exhibition</b>

# Agenda

13.45–14.15	<b>A political perspective: NHS policy, cancer patients and access to high cost-effective drugs</b> <i>Professor John Burn, Lead Clinician North East SHA</i>
14.15–14.45	<b>Understanding QALYs: Do they need to be complicated?</b> <i>Paul Trueman, York Health Economic Consortia</i>
14.45–15.05	<b>Engaging with the public: The power of communication</b> <i>Rachel Chapman, Director of Public Engagement and Communications, NHS North of Tyne, Newcastle-upon-Tyne</i>
15.05–15.35	<b>Tea/coffee break and exhibition</b>
15.35–16.35	<b>Bitesize breakout sessions (parallel sessions)*</b>  <b>Funding cancer medicine: Tariff and HRGs</b> <i>Anne Hines, Network Pharmacist, Merseyside and Cheshire Cancer Network</i> <b>Risk share schemes: Impact on the NHS</b> <i>Steve Williamson/Calum Polwart, Network Pharmacist, North of England Cancer Network</i> <b>High-cost non-cancer medicines: The NETAG experience</b> <i>Will Horsley, Lead Pharmacist, North East Treatment Advisory Group, Newcastle-upon-Tyne</i> <b>Bridging the gap: The role of third-party consultancy agencies</b> <i>Carolyn Staines, Succinct Communications</i>
16.35–16.45	<b>Summary, next steps and close</b> <i>Steve Williamson</i>